CTIC
Price:
$9.095
Market Cap:
$1.20B
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.[Read more]
Industry
Biotechnology
IPO Date
1997-03-21
Stock Exchange
NASDAQ
Ticker
CTIC
According to CTI BioPharma Corp.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.22B. This represents a change of 78.96% compared to the average of 681.17M of the last 4 quarters.
The mean historical Enterprise Value of CTI BioPharma Corp. over the last ten years is 210.67M. The current 1.22B Enterprise Value has changed 57.76% with respect to the historical average. Over the past ten years (40 quarters), CTIC's Enterprise Value was at its highest in in the December 2022 quarter at 791.38M. The Enterprise Value was at its lowest in in the March 2020 quarter at -13140880.00.
Average
210.67M
Median
176.86M
Minimum
18.78M
Maximum
708.85M
Discovering the peaks and valleys of CTI BioPharma Corp. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 429.77%
Maximum Annual Enterprise Value = 708.85M
Minimum Annual Increase = -77.77%
Minimum Annual Enterprise Value = 18.78M
Year | Enterprise Value | Change |
---|---|---|
2022 | 708.85M | 239.81% |
2021 | 208.60M | 7.56% |
2020 | 193.94M | 166.71% |
2019 | 72.71M | 287.29% |
2018 | 18.78M | -77.77% |
2017 | 84.47M | -5.27% |
2016 | 89.17M | -67.39% |
2015 | 273.42M | -7.93% |
2014 | 296.98M | 85.87% |
2013 | 159.78M | 429.77% |
The current Enterprise Value of CTI BioPharma Corp. (CTIC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
370.46M
5-year avg
240.57M
10-year avg
210.67M
CTI BioPharma Corp.’s Enterprise Value is greater than Rigel Pharmaceuticals, Inc. (310.63M), greater than Fortress Biotech, Inc. (60.71M), greater than Reviva Pharmaceuticals Holdings, Inc. (70.91M), greater than Ocuphire Pharma, Inc. (-9671816.00), greater than Protalix BioTherapeutics, Inc. (105.66M), greater than Seres Therapeutics, Inc. (191.57M), greater than Cidara Therapeutics, Inc. (41.45M), less than ImmunityBio, Inc. (2.58B), greater than Galera Therapeutics, Inc. (-6768842.00), greater than Selecta Biosciences, Inc. (69.24M), greater than Paratek Pharmaceuticals, Inc. (351.99M), greater than Corvus Pharmaceuticals, Inc. (288.04M), greater than Immutep Limited (365.43M), greater than Icosavax, Inc. (713.87M), greater than Verastem, Inc. (104.50M), less than ImmunoGen, Inc. (8.19B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Elevation Oncology, Inc. (16.72M), less than Viking Therapeutics, Inc. (4.67B), less than TG Therapeutics, Inc. (5.08B), greater than X4 Pharmaceuticals, Inc. (79.21M), greater than PDS Biotechnology Corporation (37.39M), less than Madrigal Pharmaceuticals, Inc. (6.67B),
Company | Enterprise Value | Market cap |
---|---|---|
310.63M | $302.10M | |
60.71M | $48.03M | |
70.91M | $76.39M | |
-9671816.00 | $31.74M | |
105.66M | $127.39M | |
191.57M | $164.78M | |
41.45M | $164.89M | |
2.58B | $1.95B | |
-6768842.00 | $1.69M | |
69.24M | $135.20M | |
351.99M | $127.83M | |
288.04M | $292.37M | |
365.43M | $288.21M | |
713.87M | $769.04M | |
104.50M | $176.25M | |
8.19B | $8.73B | |
915.81M | $794.69M | |
16.72M | $33.90M | |
4.67B | $4.72B | |
5.08B | $5.02B | |
79.21M | $98.42M | |
37.39M | $62.47M | |
6.67B | $6.78B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CTI BioPharma Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CTI BioPharma Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is CTI BioPharma Corp.'s Enterprise Value?
What is the highest Enterprise Value for CTI BioPharma Corp. (CTIC)?
What is the 3-year average Enterprise Value for CTI BioPharma Corp. (CTIC)?
What is the 5-year average Enterprise Value for CTI BioPharma Corp. (CTIC)?
How does the current Enterprise Value for CTI BioPharma Corp. (CTIC) compare to its historical average?